AbbVie's amylin analog ABBV-295 achieves every-other-week dosing with significant weight loss in Phase I obesity trial. Full ...
NRx Pharmaceuticals wins $11.2M DARPA funding to test NRX-101 combined with robotic TMS for treatment-resistant depression.
Varda Space Industries secures $251M Series D funding to scale space-based pharmaceutical manufacturing. Learn how orbital ...
CAS and Novartis collaborate on AI-ready reaction informatics for drug discovery. Access 160M+ curated reactions. Learn how ...
SCYNEXIS awarded $214M non-dilutive BARDA funding to advance SCY-247 antifungal candidate into Phase II trials for serious ...
Nutshell Therapeutics receives FDA IND clearance for NTS231, a novel NRF2 degrader. Discover how this breakthrough targets previously untreatable mutations.
Eli Lilly's Ebglyss meets primary endpoints in Phase IIIb ADtouch trial for moderate-to-severe hand and foot atopic dermatitis. Label expansion expected.
Immix Biopharma secures $125 million funding to advance NXC-201 CAR-T therapy for amyloidosis treatment. Learn about this ...
Aptadir Therapeutics secures €40 million seed funding led by 4BIO Capital for RNA therapeutics targeting Fragile X Syndrome.
Novo Nordisk acquires exclusive rights to Hengrui's once-weekly oral GLP-1/GIP agonist HRS-1596 for $300M upfront. Pharma ...
Ortet, a new frontier AI health lab, launches with $500M from Thoreau to build patient-centered foundation models. Learn how ...
AstraZeneca submits NDA to FDA for savolitinib plus osimertinib combination therapy for MET-driven NSCLC. Learn about this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results